LEXINGTON, Massachusetts and SYDNEY, Australia – 26 November 2013 – GI Dynamics, Inc. (ASX: GID) announced today that data on EndoBarrier® Therapy will be presented during two sessions at the International Diabetes Federation (IDF) World Diabetes Congress taking place in Melbourne, Australia on December 2-6, 2013. Hosted by IDF, an umbrella organization of more than 200 national diabetes associations from more than 160 countries, the World Diabetes Congress brings together health care professionals, diabetes associations, policymakers and companies from around the globe to share the latest findings in diabetes research and best practice.
The schedule for EndoBarrier presentations at the IDF World Diabetes Conference is as follows:
Date & Time: Tuesday, December 3, 2013 from 12:30 -12:45 p.m. AEDT
Session: Oral Presentation- Late-breaking abstracts- Basic and Clinical Science
Location: Melbourne Room 1
Presenters: David Maggs, M.D. chief medical officer, GI Dynamics
Date & Time: Tuesday, December 3, 2013 from 1 – 2 p.m. AEDT
Session: Poster: Basic and Clinical Science
Location: Poster Area
Presenter: David Maggs, M.D. chief medical officer, GI Dynamics
About EndoBarrier Therapy
EndoBarrier Therapy is a revolutionary, non-surgical, non-pharmaceutical treatment proven to help people living with uncontrolled type 2 diabetes and obesity achieve rapid and dramatic reductions in blood sugar levels, as well as substantial weight loss. EndoBarrier Therapy is a convenient and discreet treatment for people whose diabetes medications are no longer effective, who are at risk for serious health complications and who want to avoid the progression to daily insulin injections. This first-of-its-kind therapy is helping patients around the world fight their battle against type 2 diabetes and obesity while providing a pathway to a healthier lifestyle. For more information, please visit www.endobarrier.com.
About GI Dynamics
GI Dynamics, Inc. (ASX: GID) is the developer and marketer of EndoBarrier®, a breakthrough device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our EndoBarrier® including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrollment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. GI Dynamics does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. GI Dynamics may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, described in “Risk Factors” in our Prospectus lodged with the Australian Securities & Investments Commission on 3 August 2011.
|Investor Enquiries:||Media Enquiries:|
Robert Crane, Chief Financial Officer
+1 (781) 357-3250
Susan Heins, Pure Communications Inc.
+1 (864) 286-9597
David Allen or John Granger, Hawkesbury Partners Pty Limited
+61 2 9325 9046
Haley Price, Buchan Consulting Group
+61 3 8866 1215